Trial · NCT01214421
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271) | Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) | 28.66 | Standard Deviation 26.14 | percent change | |
| Percent Change From the Baseline in Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in This Study (156-08-271) | Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) | 30.58 | Standard Deviation 27.21 | percent change | |
Change From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271) | Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) | -16.77 | Standard Deviation 13.16 | mL/min/1.73 square meters (m^2) | |
Change From the Baseline in Estimated Glomerular Filtration Rate (eGFR) as Assessed by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) for Study 156-04-251 Participants Enrolled in This Study (156-08-271) | Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) | -19.92 | Standard Deviation 16.40 | mL/min/1.73 square meters (m^2) | |
| Annualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-271 | Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) | 6.164 | percent change in TKV/participant-years | ||
| Annualized Slope of Total Kidney Volume (TKV) for Study 156-04-251 Participants Enrolled in Study 156-08-271 | Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) | 4.960 | percent change in TKV/participant-years | ||
| Annualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271 | Tolvaptan, Early Treated (From Study 156-04-251: Tolvaptan) | -3.255 | ml/min/1.73m^2/participant-years | ||
| Annualized Slope of eGFR (CKD-EPI) for Study 156-04-251 Participants Enrolled in Study 156-08-271 | Tolvaptan, Delayed Treated (From Study 156-04-251: Placebo) | -3.142 | ml/min/1.73m^2/participant-years | ||
| Annualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271 | Tolvaptan, Delayed Treated (In Study 156-08-271) | 4.779 | percent change in TKV/participant-years | ||
| Annualized TKV Slope for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271 | Placebo (In Study 156-04-251) | 5.627 | percent change in TKV/participant-years | ||
| Annualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271 | Tolvaptan, Delayed Treated (In Study 156-08-271) | -3.211 | ml/min/1.73m^2/participant-years | ||
| Annualized Slope of Renal Function (eGFRCKD-EPI) for Study 156-04-251 Placebo Participants Enrolled in Study 156-08-271 | Placebo (In Study 156-04-251) | -3.572 | ml/min/1.73m^2/participant-years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01214421/results